Tenaya Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed November 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Column Group Opportunity III, LP filed an amended Schedule 13D/A regarding Tenaya Therapeutics, Inc. The specific amendments to beneficial ownership stake, share count, percentage ownership, or acquisition details are not disclosed in the metadata provided. The filing was submitted on November 16, 2026, but the actual amended disclosures are not included in the accessible text.
Why this rating
Schedule 13D/A amendments are routine; without actual ownership/deal details, cannot assess materiality relative to $63M market cap.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.